On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Polyglutamine (polyQ) repeat diseases
- Repeat expansion diseases (1)
- Repeat expansion diseases (2)
- Suppressing dominant disease genes
- How to accomplish reduction in expression?
- Reduction in expression by RNA interference
- A cartoon of the RNAi pathway
- Human spinocerebellar ataxia type 1 (SCA1)
- Effects of shSCA1 on mutant human ataxin-1 (1)
- Effects of shSCA1 on mutant human ataxin-1 (2)
- Testing shAtaxin1 in vivo: dendritic atrophy
- Testing shAtaxin1 in vivo: hSCA1 transgenics
- Testing shAtaxin1 in vivo: ataxia
- How to accomplish RNAi in target brain cells
- AAVs - deliver genetic material to the brain (1)
- AAVs - deliver genetic material to the brain (2)
- Testing shAtaxin1 in vivo: delivery issues
- shSCA1 and shLacZ transcripts in cerebellum
- shSCA1: impact on behavior
- Advantage of half-transduced lobules
- Photomicrographs from half-transduced lobules
- shSCA1 normalizes molecular layer widths
- shSCA1 reduces ataxin-1 aggregates
- Summary (1)
- Huntington's disease: a brief history
- Huntington's disease (HD)
- Mutant huntingtin expression downstream effects
- Designing shRNAs for huntingtin
- shHD2.1 reduces HD-N171-82Q mRNA
- shHD2.1 reduces HD-N171-82Q Protein
- Testing shHD in vivo
- shRNA delivery to mouse brain using AAV1
- shHD2.1 reduces transgene expression in vivo
- shHD2.1 reduces Htt-immunoreactive inclusions
- shHD2.1 improves rotarod performance in mice
- Gait abnormalities in HD mice
- shHD2.1 improves stride length in mice
- Summary (2)
- Acknowledgements
Topics Covered
- Brain diseases and molecular therapies
- RNA interference
- Mice models of brain disease
- Viral vectors
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Davidson, B.L. (2007, October 1). RNA interference for neurodegenerative diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/FEAS8148.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Beverly L. Davidson has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.